Nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis emerging market: Preparing managed care for early intervention, equitable access, and integrating the patient perspective [0.03%]
非酒精性steatohepatitis/代谢功能障碍相关性肝病新兴市场：为早期干预、公平获取和整合患者观点做好管理医疗的准备
Bridget Flavin
Bridget Flavin
Nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) is an advanced form of liver disease that can lead to significant morbidity and mortality primarily due to hepatic complications including fibrosis,...
Relationship between social determinants of health and hospitalizations and costs in patients with major depressive disorder [0.03%]
社会决定因素与重大抑郁症患者住院和费用的关系
Christie Teigland,Iman Mohammadi,Barnabie C Agatep et al.
Christie Teigland et al.
Background: The relationship of patient characteristics and social determinants of health (SDOH) with hospitalizations and costs in patients with major depressive disorder (MDD) has not been assessed using real-world data...
Budget impact models for lung cancer interventions: A systematic literature review [0.03%]
肺癌预算影响模型的系统文献回顾
Michael Willis,Andreas Nilsson,Klas Kellerborg et al.
Michael Willis et al.
Background: Budget impact models (BIMs) forecast the financial implications of adopting new technologies and the potential need for budget reallocation, thus playing a crucial role in reimbursement decisions. Despite the ...
Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis [0.03%]
美国Medicare支气管扩张症患者的治疗模式、医疗资源利用和成本的现实世界研究
Joseph Tkacz,Benjamin Lewing,Joseph Feliciano et al.
Joseph Tkacz et al.
Background: Bronchiectasis carries a significant economic burden with high health care expenditures associated with frequent hospitalizations, physician visits, and treatments, including oral and intravenous antibiotics f...
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review [0.03%]
中重度溃疡性结肠炎先进疗法的真实世界疗效和安全性：系统文献回顾证据
Peter M Irving,Peter Hur,Raju Gautam et al.
Peter M Irving et al.
Background: Effectiveness and safety of advanced therapies for ulcerative colitis (UC) warrant assessment in the real world. Objective: ...
US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance [0.03%]
用于多药耐药HIV患者的LENACAPAVIR+优化背景方案(OBR)与FOSTEMSAVIR+OBR和IBALIZUMAB+OBR的美国成本效用模型
Vittoria Vardanega,Emma New,Dylan Mezzio et al.
Vittoria Vardanega et al.
Background: Heavily treatment-experienced (HTE) people with HIV (PWH) have limited treatment options owing to multidrug resistance (MDR). Lenacapavir (LEN) is indicated, in combination with other antiretrovirals, for the ...
Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment [0.03%]
基于利益相关者观点的健康技术评估中纳入家庭溢出效应的建议研究与发展
David J Campbell,Rajshree Pandey,Lisa M Bloudek et al.
David J Campbell et al.
Background: The impacts of disease and treatment on a patient's family members and informal caregivers are known as "family spillover effects." Although many formal value frameworks call for the consideration of these eff...
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer [0.03%]
早期与延迟使用阿贝西利联合治疗高危激素受体阳性/人类表皮生长因子受体2阴性早期乳腺癌的 cost-effectiveness 分析
Shao-Hsuan Chang,Mikael Svensson,Grace Hsin-Min Wang et al.
Shao-Hsuan Chang et al.
Background: Abemaciclib was newly approved for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high-risk early breast cancer (EBC). Clinical guidelines recommended abemaciclib as...
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs [0.03%]
州Copay累加调整项目禁令与患者的赔偿责任、治疗依从性和持续时间之间的关系
Achal Patel,Danny Sheinson,William B Wong
Achal Patel
Background: Health insurers have increased the use of copay accumulator adjustment programs (CAAPs) to control costs; however, some states within the United States have banned the use of CAAPs to protect patients from ris...
Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes [0.03%]
糖尿病患者使用制造商资助的药品优惠券及其换药行为的关系研究
Yang Wang,So-Yeon Kang,Mariana P Socal et al.
Yang Wang et al.
Background: Patients often use manufacturer-sponsored coupons to reduce their out-of-pocket spending. However, little is known whether coupon use is associated with medication-switching behaviors. ...